Morgan Myrmo's  Instablog

On Monday July 13, 2009, the Financial Select Sector SPDR ETF (XLF) closed at $11.81/share, up 6.39% in just one trading session. Several financials, including Goldman Sachs (GS), were set to release earnings later in the week. The thought was that if GS had good Q2 2009 earnings that the whole financial sector would continue to rally. 

This thesis proved correct as the XLF fund traded up to $12.26/share at the close of Wednesday July 15, 2009, up 4.25% from Tuesday’s close. 

I was considering investing in a small, San Diego biotech firm called Cytori Therapeutics (NASDAQ: CTYX) when the stock was about $1.75-1.80 per share this April (2009).  They have a clinical trial in Japan right now where they have used a type of proprietary technology to increase the size of women’s breasts.  My understanding is that they are combining regenerative cells and the patient’s own fat tissue to increase their breast size. The risk is that the breast may absorb the added fat over an extended period of time rendering the breasts to their original size.  However if it does take, Cytori may completely replace silicone breast implants as long as the price is competitive.  Think about it: Cytori may give women the opportunity to grow their breasts which would look and feel natural. This is a huge market but it is not the main focus or risk/reward of the Company.